Protai has built an AI-based platform that maps the course of diseases on the protein level, enhancing the ability to observe cellular function and discover new drugs.
By systematically mapping diseases on the protein level the company aims to create an entirely new layer of functional information that enables identification of therapeutic and diagnostic targets. This approach is designed to increase accuracy in drug discovery and improve the development process, substantially saving time and lowering the costs of R&D.
Protai says it has created the world’s largest and most diverse proteomic database with over 50,000 clinical samples by harmonizing large clinical datasets, as well as healthy samples from various organs and indications. After identifying the proteome of both healthy and diseased samples, the company prioritizes the higher value targets for in-vitro and in-vivo validation. The most promising targets are identified using biology, chemistry and machine learning.
The company’s approach is modality agnostic, utilizes data across a variety of therapeutic agents, and produces therapeutic leads from the combined space of small molecules, antibodies, PROTAC and other cures. The platform has the potential to discover drugs for a wide range of complex diseases.
Protai is based in Israel and has raised $8M in seed funding.